In June 2023, Lipigon Pharmaceuticals and Leaderna Therapeutics embarked on a strategic partnership to develop and commercialize Lipigon's drug candidate Lipisense®, aimed at treating dyslipidemias such as severe hypertriglyceridemia (SHTG). This collaboration leverages the strengths of both companies to efficiently advance the clinical progress of Lipisense®. Recently, Leaderna received approval to start a Phase I study in China.
In June 2023, Lipigon Pharmaceuticals and Leaderna Therapeutics embarked on a strategic partnership to develop and commercialize Lipigon's drug candidate Lipisense®, aimed at treating dyslipidemias such as severe hypertriglyceridemia (SHTG). This collaboration leverages the strengths of both companies to efficiently advance the clinical progress of Lipisense®. Recently, Leaderna received approval to start a Phase I study in China.
Discover more about the ongoing efforts and future prospects for Lipisense® on Lipigon's website.
For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: stefan@lipigon.se
Phone: +46 705 78 17 68
About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigon initially focuses on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigon's pipeline includes three active projects: the RNA drug Lipisense® targeting elevated triglycerides, with Phase II studies approved in February 2024; an RNA drug for treating lung damage; and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen Inc. Read more at www.lipigon.se.
The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.